PHARMACOKINETICS OF ORAL NIFEDIPINE - RELEVANCE OF THE DISTRIBUTION PHASE

被引：17

作者：

HOYOVADILLO, C

CASTANEDAHERNANDEZ, G

HERRERA, JE

VIDALGARATE, J

SALAZAR, LA

MORENORAMOS, A

CHAVEZ, F

TENA, I

HONG, E

机构：

[1] INST POLYTECH NACL,CTR INVEST & ESTUDIOS AVANZADOS,DEPT FARMACOL & TOXICOL,SECC TERAPEUT EXPTL,MEXICO CITY 14000,DF,MEXICO

[2] HOSP GEN DR MIGUEL SILVA,DEPT INVEST CLIN & BIOMED,MORELIA,MICHOACAN,MEXICO

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 1989年 / 29卷 / 03期

关键词：

D O I：

10.1002/j.1552-4604.1989.tb03322.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：251 / 256

页数：6

共 22 条

[1] NIFEDIPINE THERAPY FOR CORONARY-ARTERY SPASM - EXPERIENCE IN 127 PATIENTS [J].

ANTMAN, E ;

MULLER, J ;

GOLDBERG, S ;

MACALPIN, R ;

RUBENFIRE, M ;

TABATZNIK, B ;

LIANG, CS ;

HEUPLER, F ;

ACHUFF, S ;

REICHEK, N ;

GELTMAN, E ;

KERIN, NZ ;

NEFF, RK ;

BRAUNWALD, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (23) :1269-1273

[2] ACUTE AND LONG-TERM HYPOTENSIVE EFFECTS AND PLASMA-CONCENTRATIONS OF NIFEDIPINE IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].

AOKI, K ;

SATO, K ;

KAWAGUCHI, Y ;

YAMAMOTO, M .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 23 (03) :197-201

[3] NIFEDIPINE IN THE TREATMENT OF HYPERTENSION - REPORT OF A DOUBLE-BLIND CONTROLLED TRIAL [J].

BAYLEY, S ;

DOBBS, RJ ;

ROBINSON, BF .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 14 (04) :509-512

[4]

DAHMEN W, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1842

[5] A COMPARISON OF THE HEMODYNAMIC-EFFECTS OF NIFEDIPINE, NISOLDIPINE AND NITRENDIPINE IN MAN [J].

DEBBAS, NMG ;

JACKSON, SHD ;

TURNER, P .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (04) :393-397

[6]

FLECKENSTEIN A, 1975, 3RD INT AD S, P1

[7] NIFEDIPINE KINETICS AND BIOAVAILABILITY AFTER SINGLE INTRAVENOUS AND ORAL DOSES IN NORMAL SUBJECTS [J].

FOSTER, TS ;

HAMANN, SR ;

RICHARDS, VR ;

BRYANT, PJ ;

GRAVES, DA ;

MCALLISTER, RG .

JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 23 (04) :161-170

[8]

GIBALDI M, 1975, PHARMACOKINETICS, P80

[9]

GIUNTOLI F, 1981, CURR THER RES CLIN E, V30, P447

[10]

GOLDSTEIN A, 1974, PRINCIPLES DRUG ACTI, P333

← 1 2 3 →